New concepts in antimicrobial resistance in cystic fibrosis respiratory infections.
Antimicrobial resistance
Antimicrobial strategies
Antimicrobial susceptibility testing
Biofilm
Pathoadaptation
Resistome
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
16
08
2022
revised:
09
10
2022
accepted:
12
10
2022
pubmed:
22
10
2022
medline:
7
12
2022
entrez:
21
10
2022
Statut:
ppublish
Résumé
In this review, we summarize the main points that were raised and highlighted during the pre-conference meeting to the 17
Identifiants
pubmed: 36270946
pii: S1569-1993(22)01387-X
doi: 10.1016/j.jcf.2022.10.005
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
937-945Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL141669
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest P.D. reports personal fees from Vertex Pharmaceuticals, Chiesi CZ and I.T.A.-Intertact outside the submitted work. P-R. B. reports grants and/or personal fees from Vertex Pharmaceuticals, GlaxoSmithKline, AstraZeneca, Chiesi, Insmed, Viatris, Zambon, Pari, Pfizer, Boehringer Ingelheim outside the submitted work. J.C.D. reports grants and/or personal fees from UK CF Trust, CF Foundation, CF Ireland, EPSRC, Vertex Pharmaceuticals, Boehringer Ingelheim, Eloxx, Algipharma, Abbvie, Arcturus, Enterprise Therapeutics, Recode, LifeArc, Genentech outside the submitted work. All other authors have no conflicts of interest.